A retrospective evaluating the safety profile of nivolumab in HCC in a real-world setting
Latest Information Update: 20 Aug 2021
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Aug 2021 New trial record
- 03 Jul 2021 Results presented at the 23rd World Congress on Gastrointestinal Cancer